Overview

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults

Status:
Completed

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of MW031 and Prolia® in healthy adults.

Phase:

Phase 1

Details

Lead Sponsor:

Mabwell (Shanghai) Bioscience Co., Ltd.

Treatments:

Denosumab